272 related articles for article (PubMed ID: 10529676)
1. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
[No Abstract] [Full Text] [Related]
2. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
3. Inhibitor development in patients with hemophilia: an overview.
Leissinger CA
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S1-2. PubMed ID: 16690370
[No Abstract] [Full Text] [Related]
4. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
5. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
[No Abstract] [Full Text] [Related]
6. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts HR
Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
[No Abstract] [Full Text] [Related]
7. The German National Immune Tolerance Registry, 1997 update. Study Group of German Haemophilia Centres.
Lenk H
Vox Sang; 1999; 77 Suppl 1():28-30. PubMed ID: 10529683
[No Abstract] [Full Text] [Related]
8. Factor IX antibody and immune tolerance.
Warrier I
Vox Sang; 1999; 77 Suppl 1():70-1. PubMed ID: 10529693
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
10. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
11. Inhibitors in haemophilia: a primer.
DiMichele DM
Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
[No Abstract] [Full Text] [Related]
12. Immune tolerance in children with factors VIII and IX inhibitors: a single centre experience.
Mathias M; Liesner R; Hann I; Khair K
Haemophilia; 2005 Jul; 11(4):340-5. PubMed ID: 16011585
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor development in prospective clinical trials with recombinant factor VIII preparations in previously untreated patients.
Lusher JM
Vox Sang; 1999; 77 Suppl 1():9. PubMed ID: 10529677
[No Abstract] [Full Text] [Related]
14. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX.
Knöbl P; Derfler K
Vox Sang; 1999; 77 Suppl 1():57-64. PubMed ID: 10529691
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
[TBL] [Abstract][Full Text] [Related]
16. The management of hemophilia patients with inhibitors.
Nilsson IM
Transfus Med Rev; 1992 Oct; 6(4):285-93. PubMed ID: 1421831
[No Abstract] [Full Text] [Related]
17. Inhibitors in congenital coagulation disorders.
Key NS
Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
[TBL] [Abstract][Full Text] [Related]
18. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
[TBL] [Abstract][Full Text] [Related]
19. Overview of inhibitors.
Astermark J
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S3-7. PubMed ID: 16690373
[TBL] [Abstract][Full Text] [Related]
20. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K; Schwarz P; Kunschak M
Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
[No Abstract] [Full Text] [Related]
[Next] [New Search]
